Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ZIJUN XU-MONETTE and KEN HE YOUNG.
ZIJUN XU-MONETTE
Connection Strength
12.143
KEN HE YOUNG
  1. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma. Oncoimmunology. 2024; 13(1):2384667.
    View in: PubMed
    Score: 0.975
  2. Tumor-Infiltrating Normal B Cells Revealed by Immunoglobulin Repertoire Clonotype Analysis Are Highly Prognostic and Crucial for Antitumor Immune Responses in DLBCL. Clin Cancer Res. 2023 12 01; 29(23):4808-4821.
    View in: PubMed
    Score: 0.930
  3. Therapeutic vaccines for aggressive B-cell lymphoma. Leuk Lymphoma. 2020 12; 61(13):3038-3051.
    View in: PubMed
    Score: 0.742
  4. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017; 8:1597.
    View in: PubMed
    Score: 0.614
  5. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018 01 04; 131(1):68-83.
    View in: PubMed
    Score: 0.611
  6. The TP53 tumor suppressor and autophagy in malignant lymphoma. Autophagy. 2012 May 01; 8(5):842-5.
    View in: PubMed
    Score: 0.415
  7. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012 Apr 19; 119(16):3668-83.
    View in: PubMed
    Score: 0.409
  8. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma. Front Immunol. 2024; 15:1335689.
    View in: PubMed
    Score: 0.235
  9. Correction: Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death Dis. 2024 Jan 09; 15(1):19.
    View in: PubMed
    Score: 0.234
  10. Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death Dis. 2023 11 25; 14(11):771.
    View in: PubMed
    Score: 0.232
  11. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp Hematol Oncol. 2023 Aug 14; 12(1):72.
    View in: PubMed
    Score: 0.228
  12. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Adv. 2023 04 11; 7(7):1308-1311.
    View in: PubMed
    Score: 0.222
  13. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. Int J Mol Sci. 2023 Mar 13; 24(6).
    View in: PubMed
    Score: 0.221
  14. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983.
    View in: PubMed
    Score: 0.206
  15. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr?m macroglobulinemia. Neoplasia. 2021 04; 23(4):361-374.
    View in: PubMed
    Score: 0.193
  16. Predictive Model for Idiopathic Multicentric Castleman Disease Supporting Treatment Decisions. Oncologist. 2021 01; 26(1):4-6.
    View in: PubMed
    Score: 0.189
  17. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Adv. 2020 07 28; 4(14):3391-3404.
    View in: PubMed
    Score: 0.184
  18. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. J Immunother Cancer. 2019 10 22; 7(1):272.
    View in: PubMed
    Score: 0.175
  19. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol. 2019; 9:107.
    View in: PubMed
    Score: 0.167
  20. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunol Res. 2019 04; 7(4):644-657.
    View in: PubMed
    Score: 0.167
  21. Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations. Ann Transl Med. 2018 Jun; 6(11):236.
    View in: PubMed
    Score: 0.159
  22. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Am J Surg Pathol. 2017 Oct; 41(10):1309-1321.
    View in: PubMed
    Score: 0.152
  23. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. Blood. 2017 03 23; 129(12):1658-1668.
    View in: PubMed
    Score: 0.144
  24. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood. 2016 12 29; 128(26):3083-3100.
    View in: PubMed
    Score: 0.142
  25. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
    View in: PubMed
    Score: 0.137
  26. Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2016 07 15; 22(14):3593-605.
    View in: PubMed
    Score: 0.136
  27. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016 Feb; 8(2):345-65.
    View in: PubMed
    Score: 0.135
  28. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
    View in: PubMed
    Score: 0.134
  29. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2015 Dec; 28(12):1555-73.
    View in: PubMed
    Score: 0.133
  30. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
    View in: PubMed
    Score: 0.131
  31. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
    View in: PubMed
    Score: 0.130
  32. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015 Mar 20; 6(8):5615-33.
    View in: PubMed
    Score: 0.127
  33. Epstein-Barr virus-positive nodular lymphocyte predominant Hodgkin lymphoma. Ann Diagn Pathol. 2014 Aug; 18(4):203-9.
    View in: PubMed
    Score: 0.119
  34. Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications. Hum Pathol. 2013 Dec; 44(12):2658-67.
    View in: PubMed
    Score: 0.115
  35. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 Oct 10; 122(15):2630-40.
    View in: PubMed
    Score: 0.114
  36. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012 Nov 08; 120(19):3986-96.
    View in: PubMed
    Score: 0.107
  37. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21.
    View in: PubMed
    Score: 0.107
  38. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 Oct 01; 30(28):3460-7.
    View in: PubMed
    Score: 0.105
  39. Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component. Am J Surg Pathol. 2011 Feb; 35(2):177-89.
    View in: PubMed
    Score: 0.096
  40. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023 10; 37(10):2094-2106.
    View in: PubMed
    Score: 0.057
  41. ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells. Br J Haematol. 2023 Oct; 203(2):244-254.
    View in: PubMed
    Score: 0.057
  42. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant. 2023 09; 58(9):1000-1007.
    View in: PubMed
    Score: 0.056
  43. Targetable vulnerability of deregulated FOXM1/PLK1 signaling axis in diffuse large B cell lymphoma. Am J Cancer Res. 2022; 12(10):4666-4679.
    View in: PubMed
    Score: 0.054
  44. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Am J Cancer Res. 2022; 12(9):4227-4240.
    View in: PubMed
    Score: 0.053
  45. Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study. Leuk Lymphoma. 2022 12; 63(13):3082-3091.
    View in: PubMed
    Score: 0.053
  46. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. Blood Adv. 2022 04 12; 6(7):2254-2266.
    View in: PubMed
    Score: 0.052
  47. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer J. 2022 02 01; 12(2):25.
    View in: PubMed
    Score: 0.051
  48. EBV+ high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study. Histopathology. 2022 Feb; 80(3):575-588.
    View in: PubMed
    Score: 0.051
  49. Transducin ?-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica. 2021 11 01; 106(11):2927-2939.
    View in: PubMed
    Score: 0.050
  50. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. Blood. 2021 08 12; 138(6):452-463.
    View in: PubMed
    Score: 0.050
  51. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology. 2021; 10(1):1928365.
    View in: PubMed
    Score: 0.049
  52. MYD88 L265P elicits mutation-specific ubiquitination to drive NF-?B activation and lymphomagenesis. Blood. 2021 03 25; 137(12):1615-1627.
    View in: PubMed
    Score: 0.048
  53. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
    View in: PubMed
    Score: 0.047
  54. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol. 2020 11 04; 13(1):148.
    View in: PubMed
    Score: 0.047
  55. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. Oncologist. 2020 11; 25(11):963-973.
    View in: PubMed
    Score: 0.047
  56. Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia. Cell Death Dis. 2020 09 18; 11(9):778.
    View in: PubMed
    Score: 0.047
  57. Targeting PD-L1 in non-small cell lung cancer using CAR T cells. Oncogenesis. 2020 Aug 13; 9(8):72.
    View in: PubMed
    Score: 0.046
  58. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up. Blood Cancer J. 2020 05 04; 10(5):49.
    View in: PubMed
    Score: 0.045
  59. Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation. J Hematol Oncol. 2020 05 01; 13(1):40.
    View in: PubMed
    Score: 0.045
  60. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1367-1377.
    View in: PubMed
    Score: 0.045
  61. Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas. J Natl Cancer Inst. 2020 01 01; 112(1):95-106.
    View in: PubMed
    Score: 0.044
  62. Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant. Nat Commun. 2019 11 07; 10(1):5061.
    View in: PubMed
    Score: 0.044
  63. Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice. J Hematol Oncol. 2019 07 05; 12(1):70.
    View in: PubMed
    Score: 0.043
  64. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019 06; 32(6):741-754.
    View in: PubMed
    Score: 0.042
  65. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice. Cancer Lett. 2019 01; 440-441:135-144.
    View in: PubMed
    Score: 0.041
  66. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. Blood. 2018 10 25; 132(17):1805-1817.
    View in: PubMed
    Score: 0.040
  67. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia. 2018 06; 20(6):574-593.
    View in: PubMed
    Score: 0.039
  68. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. J Pathol. 2018 05; 245(1):61-73.
    View in: PubMed
    Score: 0.039
  69. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. Br J Cancer. 2017 Nov 21; 117(11):1685-1688.
    View in: PubMed
    Score: 0.038
  70. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017 Aug; 187(8):1700-1716.
    View in: PubMed
    Score: 0.037
  71. NF-?B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 06; 30(6):854-876.
    View in: PubMed
    Score: 0.036
  72. RelA NF-?B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. Aging (Albany NY). 2016 12 08; 8(12):3321-3340.
    View in: PubMed
    Score: 0.036
  73. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016 Dec 06; 7(49):80599-80611.
    View in: PubMed
    Score: 0.036
  74. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker. Oncotarget. 2016 Apr 05; 7(14):18036-49.
    View in: PubMed
    Score: 0.034
  75. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Oncotarget. 2016 Jan 19; 7(3):2401-16.
    View in: PubMed
    Score: 0.034
  76. Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest. 2016 Feb; 126(2):653-66.
    View in: PubMed
    Score: 0.034
  77. Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. Oncotarget. 2015 Sep 15; 6(27):23157-80.
    View in: PubMed
    Score: 0.033
  78. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Mod Pathol. 2015 Oct; 28(10):1297-314.
    View in: PubMed
    Score: 0.033
  79. Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. Mod Pathol. 2015 Sep; 28(9):1202-13.
    View in: PubMed
    Score: 0.032
  80. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary? Oncotarget. 2015 Jun 10; 6(16):13933-45.
    View in: PubMed
    Score: 0.032
  81. The oncogenic microRNA miR-21 promotes regulated necrosis in mice. Nat Commun. 2015 May 20; 6:7151.
    View in: PubMed
    Score: 0.032
  82. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer. 2015 Apr 08; 15:235.
    View in: PubMed
    Score: 0.032
  83. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol. 2015 Apr 20; 33(12):1379-88.
    View in: PubMed
    Score: 0.032
  84. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget. 2015 Mar 20; 6(8):5597-614.
    View in: PubMed
    Score: 0.032
  85. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun. 2014 Oct 17; 5:5218.
    View in: PubMed
    Score: 0.031
  86. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res. 2014 Oct 01; 20(19):5113-23.
    View in: PubMed
    Score: 0.031
  87. Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma. Mol Carcinog. 2015 Oct; 54(10):1060-9.
    View in: PubMed
    Score: 0.030
  88. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014 Jun 15; 120(12):1818-29.
    View in: PubMed
    Score: 0.030
  89. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries. Clin Cancer Res. 2014 May 01; 20(9):2338-49.
    View in: PubMed
    Score: 0.030
  90. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014 Jul; 27(7):958-71.
    View in: PubMed
    Score: 0.029
  91. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20.
    View in: PubMed
    Score: 0.029
  92. Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas. Am J Pathol. 2013 Oct; 183(4):1306-17.
    View in: PubMed
    Score: 0.029
  93. Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 30; 121(22):4529-40.
    View in: PubMed
    Score: 0.028
  94. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013 May 16; 121(20):4021-31; quiz 4250.
    View in: PubMed
    Score: 0.028
  95. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013 Apr 04; 121(14):2715-24.
    View in: PubMed
    Score: 0.027
  96. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013 Feb; 98(2):255-63.
    View in: PubMed
    Score: 0.027
  97. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am J Surg Pathol. 2012 Apr; 36(4):612-9.
    View in: PubMed
    Score: 0.026
  98. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood. 2011 Jul 28; 118(4):1034-40.
    View in: PubMed
    Score: 0.024
  99. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011 Mar 24; 117(12):3391-401.
    View in: PubMed
    Score: 0.024
  100. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2011 Feb; 152(3):284-94.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.